English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduNational Comprehensive Cancer Network’s Oncology Research Program to oversee projects from early-career investigators advancing key areas for study in cancer care and biology, such as novel combination therapy, equitable access to cellular therapies, immune cell dysfunction, liquid biomarkers, genetic ancestry, oncogenic vulnerabilities, and MAIT cell antitumor activity.
Tag: NCCN
NCCN Announces Funding for Early-Stage Non-Small Cell Lung Cancer Projects, in Collaboration with AstraZeneca
The National Comprehensive Cancer Network’s Oncology Research Program to oversee projects focused on improving patient care and outcomes in early-stage non-small cell lung cancer in collaboration with AstraZeneca.
NCCN Announces Funding for Prostate Cancer Research Projects, in Collaboration with Pfizer and Astellas
The National Comprehensive Cancer Network’s Oncology Research Program to oversee projects focused on the use of enzalutamide in treating people with prostate cancer.
NCCN Works with Polish Health Leaders to Improve Cancer Standardization, Coordination, and Outcomes
International collaboration involving NCCN and Polish oncology officials publishes first of several evidence-based expert consensus guidelines with latest cancer treatment recommendations, adapted for regional needs, beginning with cervical cancer.
NCCN Publishes New Guide to Improving Knowledge and Quality of Life for Small Cell Lung Cancer Patients
NCCN announces the publication of new NCCN Guidelines for Patients®: Small Cell Lung Cancer (SCLC), which is a neuroendocrine tumor type of lung cancer that is linked to smoking and tends to be aggressive. This guide is free to view or download at NCCN.org/patientguidelines and is funded by NCCN Foundation®.
Are Too Many Phase III Cancer Clinical Trials Set Up to Fail?
New research in JNCCN finds four out of five cancer therapies tested in Phase III trials do not achieve clinically-meaningful benefit in prolonging survival, and is the first study to quantify the number of false-positive, false-negative, and true-negative trial results.
NCCN Policy Summit Explores the Promise and Challenges of New Technologies in Cancer Care
Participants at National Comprehensive Cancer Network (NCCN) Virtual Policy Summit discuss the potential for imaging and other emerging technologies to improve cancer care while not increasing disparities.
JNCCN Study Reveals Neuroendocrine Tumor Mortality Patterns to Inform Treatment Decisions
New study in JNCCN finds that among all patients with neuroendocrine tumors (NETs), the risk of dying of cancer was higher than that of dying of other causes, but mortality varies by primary tumor site, in first population-based cohort study on cancer-specific death after a NET diagnosis.
Cancer Guidelines Organization Supports Mandatory COVID-19 Vaccination for Health Workers
National Comprehensive Cancer Network (NCCN) COVID-19 Vaccination Advisory Committee calls for healthcare workforce vaccine requirements to assure healthcare community is doing all it can to prevent exposure to COVID-19.
JNCCN Study Highlights Gaps in Patient Supportive Services at U.S. Cancer Centers
New research in the July 2021 issue of JNCCN indicates a need to increase substance use and mental health support capabilities at cancer centers across the United States. Researchers found 85.4% of centers offered mental health services but only 45.5% had chemical dependency services.
NCCN Announces Selected Projects to Study Neratinib in Collaboration with Puma Biotechnology, Inc.
The NCCN Oncology Research Program (ORP) announces projects that have been selected for funding to evaluate neratinib in various tumor types, supported by a grant from Puma Biotechnology, Inc.
NCCN Maintains Qualification as CMS-Approved Provider-Led Entity for the Development of Imaging Appropriate Use Criteria
NCCN, an alliance of 31 leading cancer centers, has again qualified as a provider-led entity (PLE) for the Medicare Appropriate Use Criteria (AUC) Program by Centers for Medicare & Medicaid Services (CMS), the nation’s largest health payer.
New Patient Guide from NCCN Jumpstarts Important Conversations About Anal Cancer
New and updated patient and caregiver resources from National Comprehensive Cancer Network (NCCN) offer jargon-free, state-of-the-art information on diagnosis, treatment, and surveillance for anal, colon, and rectal cancers.
NCCN Policy Summit Explores How COVID-19 Pandemic Can Lead to Improvements in Cancer Care
NCCN Policy Summit examines the impact of the past year on oncology policy in the U.S., such as resuming recommended screening and clinical trials, applying health innovations from the COVID-19 pandemic to cancer treatment, and addressing systemic inequalities that lead to disparities in outcomes.
NCCN Cancer Experts Answer Questions about COVID-19 Vaccines
National Comprehensive Cancer Network’s patient information team provides a patient and caregiver version of recently-updated, evidence-based expert consensus recommendations for vaccinating people with cancer against COVID-19.
New NCCN Employer Toolkit Enables Organizations to Help Workers with Cancer
Free resource from the National Comprehensive Cancer Network helps employers select health plans and provide services to improve employee outcomes and minimize disruptions from cancer diagnoses—now available at NCCN.org/employertoolkit
NCCN Annual Award Honors Dr. Mary Daly for Key Contributions to Guidelines Program; Recognizes Meetings Department Director with Staff Award
NCCN annual award recognizes Dr. Mary Daly for her pioneering role in the field of genetics and family history in assessing cancer risk, particularly for breast, ovarian, and pancreatic cancers.
NCCN Foundation Announces Awards for Rising Cancer Research Leaders
National Comprehensive Cancer Network announces recipients of 2021 NCCN Foundation Young Investigator Awards; projects from early-career investigators to advance research in cancer prevention, racial disparities in screening, immunotherapy, new insights in radiotherapy, and CAR T-cell therapy.
NCCN Announces UC Davis Comprehensive Cancer Center as 31st Member Institution
NCCN announced that it has elected University of California (UC) Davis Comprehensive Cancer Center as its newest Member Institution joining 30 other leading academic cancer centers to improve and facilitate quality, effective, efficient, and accessible cancer care so patients can live better lives.
NCCN Announces New Biosimilars Research Projects in Oncology in Collaboration with Pfizer
National Comprehensive Cancer Network Oncology Research Program selects ten projects to receive funding to study the safe, effective, and efficient adoption of biosimilars in oncology.
Leading Health and Cancer Advocacy Groups Unite to Reduce Racial Disparities in Cancer Care
The National Comprehensive Cancer Network (NCCN), American Cancer Society Cancer Action Network (ACS CAN) and the National Minority Quality Forum (NMQF) presented new ideas for overcoming inequality in oncology. The recommendations address how medical systems often disproportionately fail minority patients.
New NCCN Guidelines Analyze Evidence for Cancer Type Found Almost Exclusively in Children
National Comprehensive Cancer Network publishes first-ever complete medical guidelines for a pediatric solid tumor, so children everywhere receive the best care based on the latest research. NCCN Guidelines for Wilms Tumor shares information for earlier, safer diagnosis and treatment in effort to reduce disparities; doctors warn of late diagnosis as a possible impact from the COVID-19 pandemic.
Unexpected Findings on Weight Loss and Breast Cancer from International Study in JNCCN
New research in the February 2021 issue of JNCCN examined body mass index (BMI) data for people with HER2-positive early breast cancer, and found a 5% weight loss in patients over two years in was associated with worse outcomes. Weight gain over the same time period did not affect survival rates.
Patrick Delaney Named New Executive Director of NCCN Foundation
The National Comprehensive Cancer Network® (NCCN®) today announced the appointment of Patrick Delaney as incoming Executive Director for the NCCN Foundation®. Delaney has previously held leadership roles with the Juvenile Diabetes Research Foundation, American Red Cross, and American Cancer Society.
NCCN Gets Personal About Improving Global Cancer Care for World Cancer Day
For World Cancer Day 2021, National Comprehensive Cancer Network (NCCN) employees took part in a 21-day challenge to get personal about cancer care, by sharing a look at how different staff members’ lives have been directly impacted by cancer.
Leading Cancer Organizations Warn Cancer Doesn’t Stop for COVID-19 and Neither Should You
The National Comprehensive Cancer Network (NCCN) and the American Cancer Society (ACS) are teaming up with leading cancer organizations across the country to endorse prioritizing the safe resumption of cancer screening and treatment during the ongoing COVID-19 pandemic. The coalition of 76 organizations is releasing an open letter about the threat cancer still poses to people’s health and a reminder that acting as soon as is safely possible can lead to much better outcomes in the future.
NCCN Shares New Guidance Principles for Vaccinating People with Cancer Against COVID-19
The National Comprehensive Cancer Network put out new guidance for COVID-19 vaccinations in people with cancer, based on available evidence plus consensus from top hematology and oncology experts with particular expertise in infectious diseases, vaccine development and delivery, and medical ethics.
Crystal Denlinger Named Chief Scientific Officer for National Comprehensive Cancer Network
The National Comprehensive Cancer Network (NCCN) announces Crystal S. Denlinger, MD, FACP, as incoming Senior Vice President, Chief Scientific Officer. Dr. Denlinger will help to steer strategic direction for the nonprofit as well as oversee the NCCN Oncology Research Program (ORP).
New Research in JNCCN Highlights Dangerous Disparities for Life-Saving Cancer Screening
New research in the January 2021 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds more than a third of eligible people miss timely screening tests for colorectal cancer and at least a quarter appear to miss timely screening tests for breast and cervical cancers.
NCCN Announces Research Projects Exploring Axitinib in Various Cancers, in Collaboration with Pfizer
National Comprehensive Cancer Network Oncology Research Program announces selected studies on adding axitinib, an oral VEGF inhibitor, to treatment for melanoma, colorectal cancer, and hepatocellular carcinoma (HCC), in collaboration with Pfizer.
NCCN Patient Advocacy Summit Emphasizes Treating Every Cancer Patient as an Individual
Virtual NCCN Policy Summit from the National Comprehensive Cancer Network explores how health policymakers can respond to the needs and wishes of people with cancer across all ages.
Grantees Awarded as Part of the Breast Cancer Research Project Between NCCN and Lilly Oncology
The NCCN Oncology Research Program (ORP) today announced five projects selected to receive funding for clinical and preclinical evaluation of abemaciclib, a cyclin dependent kinase (CDK) 4 & 6 inhibitor used in the treatment of HR+ and HER2- breast cancer.
New Research in JNCCN Evaluates Cost-Effectiveness of Olaparib, a PARP Inhibitor, for Metastatic Pancreatic Cancer
New research in the November 2020 issue of JNCCN identifies metastatic pancreatic cancer patient subgroups with the highest relative cost-effectiveness from maintenance olaparib, a PARP inhibitor.
NCCN Announces Beth Gaffney, MBA, as New Vice President of U.S. and Global Business Development
The National Comprehensive Cancer Network® (NCCN®) today announced the addition of Beth Gaffney, MBA, as the new Vice President of U.S. and Global Business Development, overseeing licensing and other collaborations.
JNCCN: New Research Finds Low Bone Health Testing Rates after Prostate Cancer Treatment
New research in the October 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds the rate of bone mineral density (BMD) testing in people with prostate cancer undergoing androgen deprivation therapy (ADT) has improved in recent years, but remains low.
Expert Breast Cancer Treatment Recommendations Based on Latest Evidence Updating for Multiple Languages
Ongoing updates are underway for NCCN Guidelines for Breast Cancer in Chinese, English, French, Japanese, Korean, Spanish, Polish, and Portuguese, free online at NCCN.org/global. Follow #NCCNGlobal for more. The NCCN Foundation is hosting free metastatic breast cancer webinars for patients and caregivers on October 8 and 12 at NCCN.org/patients.
New Guidelines for Maximizing Cures and Minimizing Side Effects in Children with Hodgkin Lymphoma
The National Comprehensive Cancer Network announces publication of new NCCN Guidelines for Pediatric Hodgkin Lymphoma, one of the most curable forms of pediatric cancer. They synthesize the latest evidence and expert-consensus to make sure every child receives appropriate, but not excessive, treatment.
New NCCN Resource for Understanding Childhood Leukemia
NCCN publishes a new patient and caregiver resource focused on a childhood cancer type. Free NCCN Guidelines for Patients: Pediatric Acute Lymphoblastic Leukemia (ALL) shares the latest expert advice for treating infants, children, and adolescents with the most common pediatric malignancy.
NCCN Policy Summit Explores How to Lower Costs for Cancer Care
NCCN Virtual Policy Summit features congressional staffers and representatives from CMS, COA, BIO, and others, discussing legislative and regulatory approaches for reducing health care costs.
New Research in JNCCN Sheds Light on Multi-Organ Adverse Events from Immunotherapy
New international research in the September 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds immunotherapy-related adverse events (irAEs) can impact more than one organ in a single patient. Multi-organ irAEs are more likely to happen sequentially rather than simultaneously.
Leading Cancer Treatment Recommendations from NCCN Now Available in French, German, Italian, Portuguese, Russian, and Spanish
NCCN Guidelines, containing expert recommendations for cancer care, are available in French, German, Italian, Portuguese, Russian, and Spanish can all be accessed for free at NCCN.org/global or via the free Virtual Library of NCCN Guidelines® App
Up-to-Date Leading Cancer Treatment Recommendations from NCCN Now Available in Chinese
NCCN announces new and updated Chinese language versions of NCCN Guidelines for AML, Breast Cancer, CLL/SLL, Colon Cancer, Gastric Cancer, Hairy Cell Leukemia, Head and Neck Cancers, Hodgkin Lymphoma, Melanoma (Cutaneous), Multiple Myeloma, Non-small Cell Lung Cancer, Primary Cutaneous Lymphomas, and T-Cell Lymphomas.
NCCN Meeting on Blood Cancers Will Be Virtual for the First Time
The NCCN Virtual Nursing Forum and Annual Congress: Hematologic Malignancies (#NCCNhem2020) will provide the latest evidence and expert consensus on emerging practices and debates in blood cancer treatment, online October 8-10.
NCCN Oncology Research Program Announces Projects Selected for Funding to Study Futibatinib in Tumors with Aberrant FGFR Expression, in Collaboration with Taiho Oncology
The NCCN Oncology Research Program (ORP) today announced four projects selected to receive funding for clinical and pre-clinical evaluation of futibatinib (TAS-120) in collaboration with Taiho Oncology.
NCCN Explores Adoption of Biosimilars in Oncology in Collaboration with Pfizer
National Comprehensive Cancer Network issues Request for Proposals (RFP) for projects that develop and validate enduring approaches to improve the safe, effective, and efficient adoption of biosimilars in oncology.
Translated Tool from NCCN Measures Mental Health “Temperature” of People with Cancer
The NCCN Distress Thermometer enables discussion and treatment of distress as part of routine care for people with cancer. This free resource is now translated into 46 languages for global accessibility.
JNCCN Study Explores if Insurance is Keeping Pace with Trends in Targeted Cancer Therapy
New research from the University of California, San Francisco (USCF) and City of Hope in the July 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network examines coverage trends for circulating tumor DNA testing, also known as gene sequencing of ctDNA or “liquid biopsies.” The researchers found coverage rate rose from 0% to 38% in three years. The policies also increased in scope from 2017-2019, going from one cancer type to 12.
NCCN: What People with Cancer and their Caregivers Need to Know about CAR T-Cell Therapy
The National Comprehensive Cancer Network (NCCN) has published a new NCCN Guidelines for Patients: Immunotherapy Side Effects focused on chimeric antigen receptor (CAR) T-cell therapy. This is book two in a series that includes another book on irAEs focused on immune checkpoint inhibitors.
How to Recognize Side-Effects from Immunotherapy? New NCCN Guidelines for Patients can Help
New NCCN Guidelines for Patients: Immunotherapy Side Effects – Immune Checkpoint Inhibitors from National Comprehensive Cancer Network and NCCN Foundation shares information for patients and caregivers on how to recognize and manage adverse events from immune checkpoint inhibitors.
NCCN Works to Improve Global Cancer Care for Children with Newly Translated Recommendations
NCCN Guidelines for Pediatric Acute Lymphoblastic Leukemia (ALL) in Chinese, Japanese, French, Spanish, and Portuguese are now available for free at NCCN.org